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Neurocardiogenic Syncope in Children and Adolescents
BLAIR P. GRUBB, MD, FACC, DANIELA SAMOIL, MD, DANIEL KOSINSKI, MD,
KATRINKA KIP, MD, PAMELA BREWSTER, MA
Toledo, Ohio
Qrs. The purposie of our study was to determine whether
the wrotooln reaptake Inhibitor sertraline hydrochloride could
prevent neurecaMiogenk syncope in children and adolescents
resistant to or Intolerant of other therapies.
Back ad'. The sersionin reuplake inhibitor Nuoxetine
bydradMoride has beets reported to be effective in preventing
neurocardkqenic syncope in adults .
meows. Seventeen consecutive young patients (mean age 15
years, nwge 10 to IS; 7 male, 10 fenale) with recurrent syncope
and a positive heakuprdight tilt table test, and in whom standard
therapies (findrocortisoat, transdermal scopolamine, beta .
%drmr* blocking agents, disopyramide) were Ineffectual,
Poorly tolerated or centraledicated, were referred for study .
Sertrallne was administered orally at 50 mil dally for 4 to 6 weeks .
Recurrent unexplained syncope is a common and often
frustrating clinical problem. Syncope annually accounts for
up to 3% of all adult emergency room visits and 69b of all
hospital admissions (1) . Although the exact incidence of
syncope in children and adolescents is unknown, it is
thought to be similar (2) . Since .,e introduction of clinical
upright tilt table testing in 1986, it has become increasingly
apparent that in many young patients, transient episodes of
vasovagally mediated hypotension and bradycardia (neuro-
cardiogenic syncope) are a frequent cause of their recurrent
fainting spells (3) . Recurrent episodes of sudden syncope
can produce a high amount of anxiety among patients and
their parents and teachers and may occasionally result in
severe bodily injury (4) . A recent study reported that the
degree of functional impairment caused by recurrent syn-
copc is comparable to that of chronic disabling disorders
such as rheumatoid arthritis (5). Head-upright tilt table
testing has greatly aided in identifying young patients sus-
ceptible to neurocardiogenic syncope and has been shown to
be useful in assessing the adequacy of prophylactic therapy
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A head-upright tilt table test was then re rfornied, acid the
clinical effect was noted .
Resufts . Three patients (18%, 95% confidence interval [Cil 1
to 44) were intolerant of the drug, and it was discontinued . Nine
patients became asymptomille and tilt negative (53%, 95% C1 26
to 76), and five remained tilt positive (36%, 95% Cl 15 to 65) .
Over a mean follow-up period of 12 :t 5 months, the tilt-negative
patients remained symptom free while taking sertrallne .
Conclusions. The serotonin reuptake inhibitor serarallne
hydrochloride can be effective in preventing recurrent nourocar-
diogenic syncope in selected patients unresponsive to or intolerant
of other therapeutic modalities .
(J Ant Coll CaMful 1994;24.490-4)
for the disorder (6-15) . However, some patients who have
recurrent neurocardiogenic syncope do not respond ade-
quately to (or are intolerant of) the current available phar-
macologic agents used to treat this problem, such as beta-
adrenergic biocking agents, transdermal scopolamine,
fludrocortisone and disopyramide . Recently, the serotonin
(5-hydroxytryptamine) reuptake inhibitor fluoxetine hydro-
chloride has been reported to be effective in up to 53% of
adult patients with recurrent neurocardiogenic syncope who
were intolerant of or unresponsive to other forms of therapy
(10). Thus, to determine whether serotonin reuptake inhibi-
tors would have similar effects in children and adolescents
with recurrent refractory neurocardiogenic syncope and
positive head-upright tilt table tests, the following study was
undertaken .
Methads
Seventeen patients with recurrent unexplained syncope
were included in this study . Syncope was defined as an
abrupt transient loss of consciousness with an inability to
maintain postural tone . Each of the patients had had at least
three syncopal episodes in the preceding 6-month period, the
etiology of which remained unclear despite a complete
history and physical examination, 12-lead electrocardiogram
(ECG), echocardiography and electroencephalography .
Twelve of the patients had undergone computed axial to-
mography of the brain, and four underwent magnetic reso-
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nance imaging (DARI) of the brain . Seven patients underwent
exercise tolerance testing . One patient underwent cardiac
catheterization and coronary angiography .
Each of the 17 patients underwent head-upright tilt table
testing after an overnight fast . The head-upright tilt table test
protocol used has been described elsewhere (2,6) . The study
protocol was approved by the Institutional Review Board,
and informed consent was obtained from the patient or
parents, or both. Patients were then connected to a standard
ECG monitor for continuous evaluation of heart rate and
rhythm. A standard sphygmomanometer was used to mea-
sure blood pressure . Respiratory rate was determined every
3 ruin by direct observation . After baseline determinations of
blood pressure and heart rate, each patient was positioned at
an angle of 80' from horizontal for up to 30 min on a weight-
bearing tilt table . Blood pressure was measured every 3 min,
and ECG recordings were done continuously . if syncope
occurred during the tilt, the patient was rapidly lowered to
the supine position, and the study ended . If no syncope
occurred during the tilt, the patient was lowered to the
supine position for 5 to 10 min, and an intravenous isopro-
terenol infusion was started at I gg/min . Upright tilt table
testing was then performed as previously described for a
period of 20 aim If it was negative, a third tilt at 2 Itg/min
was performed. A positive response was described as the
provocation of hypotension and bradycardia associated with
a loss of consciousness that reproduced the patients' clinical
episodes .
Standard therapies. Each of the 17 patients who were
included in the study exhibited a positive response during
head-upright tilt table testing. Each patient received stan-
dard pharmacotherapy, and repeat tilt table testing was
performed to access response . The following agents were
evaluated (unless contraindicated) in this order : fiudrocorti-
sone, 0 .1 mg orally twice a day ; atenolol, 50 to 100 mg, orally
once a day; transdermal scopolamine patch every 3 days ;
and disopyramide, 200 mg, controlled-release form, orally
twice a day . Restudy was performed between 5 and 14 days
after the initiation of a particular therapy . Failure was
defined as the recurrence of syncope during tilt table testing
or a clinical recurrence of syncope .
In each of the 17 patients, therapy with fludrocortisone,
beta-blockers, transdermal scopolamine or disopyramide
(either alone or in combination) was either contraindicated,
poorly tolerated or ineffectual in preventing recurrent clini-
cal syncope or upright tilt-induced syncope . In addition,
each of the patients continued to experience episodes of
syncope .
Sertrallne administration . Each of the 17 patients (and
their parents) with recurrent syncope and positive tilt table
studies who failed to respond to conventional therapies
agreed to participate in the study . Sertraline hydrochloride
was started at 50 mg orally each day . Four to six weeks later,
the response to head-upright tilt was reevaluated in the same
laboratory at approximately the same time of day using the
same protocol .
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Data analysis. Results are expressed as mean values ±
SD. Patients were classified as positive or negative for both
the tilt study and their clinical course on the basis of whether
their syncope symptoms occurred
. The sample proportions
for patients who were classified as negative on the basis of
the absence of syncope were analyzed using the binomial
distribution. Confidence intervals for the binomial propor-
tions were calculated using the exact binomial distribution,
and the reported 95% confidence intervals were based on the
1 .96 SE of the proportion . Analysis of variance was used to
determine whether there was a statistical significance be-
tween the groups on the basis of age, number of syncopal
episodes and tilt time in phase . Contingency table analysis
was used to establish whether there was an association
between the syncope groups on the basis of gender break-
down .
Results
None of the 17 patients studied (10 young women, 7
young men ; mean [±SD] age 15 ± 6 .8 years, range 10 to !8)
had any evidence of organic heart disease . Electrocardio-
graphy and echocardiography were normal m all patients .
No patient had abnormal computed axial tomography or
MRI of the brain or a history of depression . Four patients
had a history of hyperactive airways disease, and six a
history of recurrent severe headaches .
The mean number of syncopal episodes in the group was
6.8 ± 3.6 during the 6 months before the study . Two patients
had been involved in automobile accidents as a result of
syncope, one in a motorcycle accident, and one in a bicycle
accident . One patient had a severe nasal fracture during
syncope (requiring reconstructive surgery) ; one had a frac-
ture of the clavicle after falling down a set of stairs ; and one
had a zygomatic arch fracture after syncope while shower-
ing. One patient had severe facial lacerations after falling
onto gravel . In each of these patients, the clinical episodes
were described as a sudden loss of consciousness occurring
with little or no prodrome . Five of these adolescents had
been banned from returning to public school, and all had
been excluded from pi vsical education or extracurricular
activity . Two patients lost their part-time employment be-
cause of syncope .
Response to tilt table testing (Table 1) . In response to
head-upright tilt table testing alone (baseline study), I I of the
patients experienced syncope (64%) similar to what they had
experienced clinically . The mean tilt time for the baseline
positive patients was 16 ± 8 min . After upright tilt table
testing with a graded isoproterenol infusion, six additional
patients experienced syncope . The mean time to syncope
was 12 ± 5 min. Two patients (Patients 2 and 10) had asys-
tolic periods during tilt table testing.
Response to sertraline therapy . Three patients developed
side effects and eventually asked to be discontinued from the
drug. Two had complaints of nausea and diarrhea, and one
complained of headaches and nausea . The remaining 14
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Table 1 . Response to Sertraline
patients tolerated the drug well, although three patients
complained of some mild difficulty sleeping (but not enough
to discontinue use of the agent) .
Twelve patients reported having no clinical syncopal
episodes up to 4 weeks after starting the drug (the minimal
time to see an effect with sertraline) and the follow-up tilt
study. Two patients reported syncopal episodes during the
same period .
In response to repeat tilt !able testing, nine patients (53%,
95 confidence interval (CII 26 to 76) were rendered negative ;
the remaining five patients (36%, 95% CI 15 to 65) continued
to have induced hypotension and bradycardia .
The F. . . _fits who were rendered tilt negative during
sertraline therapy continued to receive it . Over a mean
follow-up period of 12 ± 5 months, these patients have
remained symptom free (one patient had a syncopal spell
after stopping sertraline but has had none since its resump-
tion, and one patient discontinued taking sertraline after
moving to another city and has since had recurrent syncopal
spells).
Of the patients who were intolerant of, or had failed,
sertraline therapy, three have continued to experience re-
current syncope, one has had no further episodes with a
combination of support hose, fluorohydrocortisone and
theophylline, and one has been lost to follow up . Three
patients who were tilt positive on sertraline asked to con-
tinue the drug; only one has had recurrent syncope .
Discussion
Recurrent episodes of neurocardiogenic syncope can be a
severely disabling condition for a young person (2) . The
F - female ; M = male; Pt = patient
; + = positive (syncope) ; - = negative (no syncope) ; 0 = not tolerated .
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unpredictable nature of these episodes not only creates an
extreme psychologic burden for the patient and their fami-
lies, but may also limit the young person's educational and
employment opportunities (5) .
Although the majority of patients who require pharmaco-
therapy will respond to the standard treatment modalities,
such as fludrocortisone (6), beta blockers (16), theophylline
(17), disopyramide (18), transdermal scopolamine (19) and
pseudoephedrine (20), there are patients for whom these
drugs are ineffective, poorly tolerated or contraindicated . On
the basis of our initial observations in adult patients that
fluoxetine hydrochloride, a serotonin reuptake inhibitor,
prevented upright tilt-induced syncope in --50% of otherwise
refractory patients, we decided to explore the potential
usefulness of serotonin reuptake inhibitors in a similar group
of pediatric patients with recurrent refractory neurocardio-
genie syncope (10) . The data presented here demonstrate
that sertraline hydrochloride was clinically significant in
preventing upright tilt-induced neurocardiogenic hypoten-
sion and bradycardia in nine (53%) of 17 young patients with
recurrent syncope (or nine [64%1 of 14, 95% CI 35 to 86, p =
0.04) who tolerated the drug .
Recurrent unexplained syncope in the young patient is
frequently believed to be neurocardiogenic (or vasovagal) in
nature. Head-upright tilt table testing has been introduced as
a promising method of identifying patients predisposed to
neurocardiogenic hypotension and bradycardia (2) . The re-
sults of head-upright tilt table testing have been demon-
strated to be reproducible and have been used as a guide to
the efficacy of pharmacotherapies used to prevent recurrent
syncope (11-13). Although the exact mechanism by which
syncope occurs is still poorly understood, it is presently
Pt NoJ
Gender
Age
(yr)
Total No .
of Syncopal
Episodes
Till Table Phase
Causing Syncope
Tilt Time in
Phase Causing
Syncope (min)
Response to Sertraline
Tilt Clinical
VF 17
16
Baseline 10
2/F 16
8
Baseline 6
3/M 17
6
Baseline
14 0 0
4/M 15
6 lsoproterenol (I pglmin)
5 0 0
51M 10
4 Baseline
18
OF 17
12
lsoproterenol (I pglnein) 12
71M
18 4
lsoprotereno) (2 pg/min) 14
8/F
14
5 Baseline 22 0 0
9/F
16
7 lsoprolerenol (2 ,ug/min)
17
10/F 17
4 Baseline
7
IIN 15
8 Bseline
27
12/F 18
3 lsoproterenol (2 µ$/min)
12 +
13/F 16
6 Baseline
23
141M IS
3 Baseline
4
151M 12 S
Baseline 21
+ +
16/F 16 12
Isoproterenol (I pglmin) IS +
17/F 17 6
Baseline
29 + +
Mean
1 .5.6
6.8
15.1
SD 2.1
3.6 7.6
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thought that a sudden increase in the degree of peripheral
vasodilation results in a sudden decrease in venous return to
the heart, leading to a rapid increase in the force of ventric-
ular contraction (14) . This increase in contractile force is
postulated to cause the activation of a large number of
mechanoreceptors located in the base of the right and left
ventricles . This dramatic increase in afferent neural traffic to
the brain stem seems to mimic the conditions that occur
during hypertension and produces an apparent "paradoxic"
reflex bradycardia and peripheral vasodilation (15) .
Therapy. Therapy for the young patient with recurrent
neurocardiogenic syncope must be individualized for each
patient because the severity of the condition varies widely .
In many young patients, syncope only occurs under excep-
tional circumstances, and the patient need only be advised to
avoid predisposing conditions . Some patients will experi-
ence a definite prodrome before syncope and can be advised
to lie down when they think an episode is imminent (15) .
However, there are some patients with recurrent and unpre-
dictable syncope that occurs with little or no warning .
Pharmacotherapy is required in this group .
Usually, most young patients who require pharmacother-
apy will respond to one (or a combination) of the aforemen-
tioned agents . Yet, there are patients in whom these drugs
arc ineffective, poorly tolerated or contraindicated . Similar
problems in older adult patients led us to investigate the use
of the serotoninn reuptake inhibitor fluoxetine hydrochloride
after anecdotal observations that patients receiving the drug
as therapy for depression showed a marked improvement in
their neurocardiogenic syncope (10) . In 16 patients with
recurrent refractory neurocardiogenic syncope who were
treated with fluoxetine hydrochloride, 20 mg orally, each day
for 5 to 6 weeks, three developed side effects requiring
discontinuation (headaches, nausea and sexual dysfunction) .
Overall, seven (44%) of 16 patieni&became tilt negative and
asymptomatic (or seven [53%] of 13 who !olerated the drug) .
These observations led us to test the effectiveness of a
similar serotonin reuptake inhibitor, sertraline hydrochlo-
ride, in the therapy of young patients with severe refractory
neurocardiogenic syncope. We found the overall response
rate in this group was similar: nine (53%) of 17 patients were
rendered tilt negative and asymptomatic, and three (17%) of
17 proved intolerant of the agent, mainly because of head-
aches and nausea .
Serotonin and syncope. The exact part played by seroto-
nin pathogenesis of neurocardiogenic syncope is unclear .
However, serotonin has been shown to be an important
component of the responses seen as a result of acute blood
loss, a mechanism essentially similar to that of neurocardio-
genic syncope (14,21) . Using an anesthetized cat model,
Elam et al . (22) found that depletion of serotonin stores
blunts the sudden decrease seen in arterial pressure and
heart rate during acute hemorrhage . Further studies have
shown that the administration of the serotonin receptor
blocker methysergide during acute hemorrhagic hypotension
has a marked pressor effect (22) . Similar studies by Hasser et
GRUBB ET AL .
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al. (23) have demonstrated that methysergide increased
blood pressure when given to conscious rabbits made hypo-
tensive by acute hemorrhage . Morgan et al . (24,25) have
reported similar findings and suggested that sympathoinhib-
itory serotonergic mechanisms in the central nervous system
may be stimulated by acute hemorrhage, thereby producing
vasodilation and bradycardia. Abboud (14) recently reported
that central intracerebrovascular serotonin induces hypoten-
sion, inhibition of renal sympathelfic-nerve activity and ex-
citation of renal sympathetic nerve activity . He further
stated that these studies raise the possibilities that serotonin
may be acting at a central level to inhibit sympathetic
activity and that serotonin antagonists may be effective in
the treatment of neurocardiogenic syncope .
Sertraline hydrochloride (Zoloft, Pfizer) is a relatively
new selective serotonin reuptake inhibitor (26) . In contrast
to the tricyclic antidepressant compounds, sertraline is char-
acterized by highly selective serotonin reuptake inhibition
with little or no affinity for adrenergic, cholinergic or hista-
mine receptors (27) . It is also considered a much more potent
serotonin reuptake blocker than fluoxetine hydrochloride
(Prozac) (24. Peak plasma concentrations of smraline are
achieved between 6 and 8 h after oral administration, and the
drug is 98% bound to plasma proteins (29). The primary
metabolite of sertraline is desmethylsertraline, which is eight
times less potent a serotonin reuptake blocker than the
parent compound (27) . Sertraline has an elimination half-life
of -26 h ; that of desmethylsertraline is -66 h (28) . Steady-
state concentrations are believed to require at least 4 weeks
of therapy (26) .
We chose to use sertraline rather than fluoxetine in this
group because of the drug's greater degree of serotonin
reuptake inhibition and reported lower side-effect profile
(26,27) . We also thought that the relatively small sertraline
tablets would be easier for the young patient to swallow
(rather than the much larger fluoxetine capsules) .
In our study group, however, the percent of patients
requiring discontinuation of the drug as a result of side
effects was the same as we observed with fluoxetine, -18%
(10). The most common side effects seen during sertraline
therapy include nausea, diarrhea and insomnia (20) .
Overall, we found sertraline to be a safe and effective
therapy for preventing head-upright tilt induced syncope in
young patients unresponsive to, or intolerant of, other
therapies. The exact mechanisms by which both sertraline
and fluoxetine exert their effects remain uncertain . We
postulate that through the enhancement of serotonergic
transmission, these agents may induce a down-regulation of
postsynaptic serotonin receptors, thereby blunting the po-
tential response to rapid shifts in cerebral serotonin levels
(10), Beta-blockers have recently been shown to have cen-
tral serotonin-blocking activities, an action that may contrib-
ute to their therapeutic effect in neurocardiogenic syncope
(30,31) .
Study limitations. There were several important limita-
tions to our study
. The study group was relatively small,
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and it was not a randomized, controlled trial . Rather, each
patient was used as his or her own control. Side effects
precluded continuation of the drug in three patients . Because
the effects of sertraline on human fetal development are
unknown, female patients should be advised not to become
pregnant while taking sertraline . In addition, neurocardio-
genic syncope may exhibit spontaneous variations in sever-
ity (15) . Therefore, we cannot be sure that the beneficial
effects noted can be wholly attributed to the actions of the
drug. Furthermore, the patients presented here tended to
have an unusually severe form of neuro cardiogenic syncope
and thus may not be representative of the majority of
patients with this disorder .
C . We conclude that sertraline hydrochloride
may an effective therapy in young patients with recurrent
episodes of neurocardiogenic and upright tilt-induced by
tension and bradycardia who are unresponsive to or poorly
tolerant of other therapies . Additional randomized, con-
trolled studies will be necessary to better define the potential
role of serotonin reuptake inhibitors in the management of
neurocardiogenic syncope and to understand the exact
mechanisms by which these effects occur.
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